Team

JPT has a work force of >150 highly trained and skilled employees. 30 of our co-workers hold a university degree and 20 have a PhD in natural sciences. Over the last 15 years our team has built a substantial know-how in all areas of peptide applications ranging from antigen discovery and immune monitoring to proteomics and immunotherapy development.

Aurélien Claeyssen (Managing Director)

Aurélien Claeyssen has been managing director of JPT Peptide Technologies since January 2024. He holds a Masters degree in Biotechnology and Management from the Faculty of Pharmacy of Grenoble and the Grenoble Management School (France). After 3 years as a business developer in life sciences, he co-founded Smartox in 2013, a peptide-based drug discovery company, and SB-PEPTIDE in 2016, a peptide CDMO company. He served as Chief Commercial Officer and Board Member.

Jens Holstein (Managing Director)

Jens Holstein is Managing Director of JPT and CFO of BioNTech SE. Prior to joining Biontech he was CFO of Morphosys AG and served in multiple CFO positions as well as general manager roles within Fresenius SE group. Jens Holstein also spend several years in the consulting industry, including holding M&A positions in Frankfurt and London. He holds a diploma of Business Administration from the University of Münster.

Dr. Sierk Poetting (Managing Director)

Dr. Sierk Poetting holds a Master of Science in Optical Sciences from the University of Arizona and a Ph.D. in Physics from the Ludwig-Maximilians-University in Munich.

From 2012 to August 2014 he worked for Novartis and served as Vice President and Chief Financial Officer for the Sandoz Division in North America.

Afterwards he took over the position as Chief Financial Officer and Chief Operating Officer at BioNTech SE.

Dr. Holger Wenschuh (former Managing Director)

Dr. Holger Wenschuh has been Managing Director at JPT Peptide Technologies from 2004 to 2023. Before, he served as Business Unit Manager at Jerini AG and Managing Director at Chemotopix GmbH. Dr. Wenschuh studied Chemistry at the Friedrich-Schiller-University in Jena, Germany, and obtained his PhD in Organic Chemistry at the Institute of Molecular Pharmacology in Berlin, Germany. He worked at the University of Massachusetts and Perseptive Biosystems, USA and from 1995 to 1997, headed the Peptide Unit at the Max-Planck-Institute of Infection Biology in Berlin. Dr. Wenschuh is author and co-author of numerous publications, co-inventor on several patents and editorial board member of the International Journal of Peptide Research and Therapeutics.